科兴生物收退市函，10年内斗停牌超6年，此前宣布分红530亿元

Core Points - The company, formerly known as the "King of Vaccines," has received a delisting notice from NASDAQ due to failure to submit its annual report for the fiscal year ending December 31, 2024, by the extended deadline [1][3] - The company has engaged UHY LLP as its new independent auditor to expedite the submission of the 2024 annual report and is actively communicating with NASDAQ to request an extension and a hearing regarding the delisting [1][3] - The company asserts that its listing status will not materially affect its core business operations, which continue to function normally, including vaccine research, production, and supply [3] Company Governance Issues - The company has faced internal governance failures for years, leading to significant turmoil, including the resignation of its previous auditing firm and a prolonged stock suspension [6][10] - A special shareholders' meeting held on July 9 resulted in the removal of the existing board and the appointment of ten new members, including the return of founder Yin Weidong [6][9] - The new board's actions have been met with resistance from the current chairman, Li Jiaqiang, who claims the special meeting was illegal, further complicating the company's governance situation [6][8] Financial Matters - The company announced a substantial dividend plan totaling $7.448 billion, with an initial payment of $55 per share, which could deplete over 70% of its cash reserves [6][7] - The total market capitalization of the company's U.S. stock is currently only $390 million, raising concerns about the sustainability of such a large dividend payout [8]